Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fabrinet (FN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Fabrinet vs State Street SPDR S&P Biotech ETF — how do they compare? Fabrinet trades at $580.59 (market cap $18.84B), while State Street SPDR S&P Biotech ETF trades at $159.02. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Fabrinet nearer its low. Which is the better fit depends on your goals.

FNXBI
Market Cap
$18.84B
Sector
TechnologyBroad Market / Factor
52-Week High
$746.47$164.28
52-Week Low
$277.04$86.92
Enterprise Value
$17.90B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fabrinet

Fabrinet (FN) trades at $571.78, up 8.48% in the last session, showing strong momentum despite a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected soon. Analyst consensus remains strongly bullish with 75% buy ratings, supported by Fabrinet's strategic positioning in AI optical manufacturing and robust revenue growth projections.

The outlook remains positive given Fabrinet's critical role in AI infrastructure and strong financial performance, though premium valuation metrics and technical overbought conditions present near-term risks. Continued execution on capacity expansion and AI-driven demand should support long-term growth, but investors should monitor supply chain constraints and competitive pressures.

State Street SPDR S&P Biotech ETF

XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.

Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Fabrinet

Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.

Read more on FN

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI